Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
Record ID 32018001092
Authors' objectives: To assess clinical and cost effectiveness.
Project Status: Completed
Year Published: 2021
URL for published report: https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2295/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland, United Kingdom
- Antineoplastic Agents
- Protein Kinase Inhibitors
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email: email@example.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.